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Abstract
The development of novel therapeutics is urgently required for diseases where existing
treatments are failing due to the emergence of resistance. This is particularly pertinent for
parasitic infections of the tropics and sub-tropics, referred to collectively as neglected tropi-
cal diseases, where the commercial incentives to develop new drugs are weak. One such
disease is schistosomiasis, a highly prevalent acute and chronic condition caused by a para-
sitic helminth infection, with three species of the genus Schistosoma infecting humans. Cur-
rently, a single 40-year old drug, praziquantel, is available to treat all infective species, but
its use in mass drug administration is leading to signs of drug-resistance emerging. To meet
the challenge of developing new therapeutics against this disease, we developed an innova-
tive computational drug repurposing pipeline supported by phenotypic screening. The
approach highlighted several protein kinases as interesting new biological targets for schis-
tosomiasis as they play an essential role in many parasite’s biological processes. Focusing
on this target class, we also report the first elucidation of the kinome of Schistosoma japoni-
cum, as well as updated kinomes of S. mansoni and S. haematobium. In comparison
with the human kinome, we explored these kinomes to identify potential targets of existing
inhibitors which are unique to Schistosoma species, allowing us to identify novel targets and
suggest approved drugs that might inhibit them. These include previously suggested schis-
tosomicidal agents such as bosutinib, dasatinib, and imatinib as well as new inhibitors such
as vandetanib, saracatinib, tideglusib, alvocidib, dinaciclib, and 22 newly identified targets
such as CHK1, CDC2, WEE, PAKA, MEK1. Additionally, the primary and secondary targets
in Schistosoma of those approved drugs are also suggested, allowing for the development
of novel therapeutics against this important yet neglected disease.
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Author summary
The rise of resistance through the intensive use of drugs targeted to treat specific infec-
tious diseases means that new therapeutics are continually required. Diseases common in
the tropics and sub-tropics, classified as neglected tropical diseases, suffer from a lack of
new drug treatments due to the difficulty in developing new drugs and the lack of market
incentive. One such disease is schistosomiasis, a major human helminth disease caused by
worms from the genus Schistosoma. It is currently treated by a 40-year old drug, prazi-
quantel, but its widespread use has led to signs of drug-resistance emerging, with no
alternative effective treatments available. To meet this challenge, we have developed an
innovative computational drug repurposing pipeline supported by experimental pheno-
typic screening. Protein kinases emerged from our pipeline as interesting new biological
targets. Given that many human kinase inhibitors have been successfully applied specially
in cancer therapy and kinases have conserved structures and functions, we also undertook
a detailed analysis of the kinases present in all infective Schistosoma species and human
host. This allowed identification of new Schistosoma-specific kinase targets and suggest
approved drugs to be used for treating schistosomiasis as well as opening new avenues to
treat this neglected disease.
Introduction
Morbidity due to helminth infections affects over one billion people, particularly in marginal-
ized, resource-constrained regions of the world, propagating a vicious circle of poverty,
decreased productivity, and inadequate socioeconomic development. One of the most preva-
lent helminth infections is schistosomiasis, an acute and chronic disease caused by parasitic
worms of the genus Schistosoma. This debilitating disease is widespread in lower and middle
income countries of the tropics and sub-tropics, with more than 200 million people affected
worldwide and an estimated 800 million at risk [1, 2]. It is second only to malaria in terms of
prevalence and social and economic impact. Three main species infect people often during
routine agricultural, domestic, occupational and recreational activities that expose them to
infested water: S. mansoni (South America and sub-Saharan Africa), S. haematobium (Africa)
and S. japonicum (South-East Asia). Lack of hygiene and certain play habits of school-aged
children such as swimming or fishing in infested water make them especially vulnerable to
infection. In the Americas, Brazil has the largest endemic area and accounts for 95% of cases
of S. mansoni in the region, with severe cases still occurring [3]. Currently there is only one
40-year-old drug, praziquantel (PZQ), which is effective against all forms of human schistoso-
miasis. Though in many respects it is still a useful antischistosomal drug, it has low efficacy
against the juvenile stage (2–4 weeks post infection) of schistosomes, a limitation that has sig-
nificant impact on the efficacy of mass drug administration (MDA) programs in endemic
areas where reinfection rates are high [4]. In addition, WHO is currently recommending PZQ
for MDA and there are concerns that this could lead to resistance and therapeutic failure [5].
Schistosomiasis is neglected by the pharmaceutical industry, yet it is still an important dis-
ease that continues to impact the poorest and most vulnerable individuals in society. As its
treatment relies on a single available drug, PZQ, with a propensity for resistance to develop to
it, discovery of novel antischistosomal drugs is of paramount importance. An important start-
ing point for the discovery for new antischistosomal therapeutics is the identification of novel
targets. One route to this is through drug repurposing, also known as drug repositioning or re-
profiling [6, 7]. It is the new application for an existing drug to a different disease and offers a
Drug repurposing and discovery for treating schistosomiasis
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highly attractive means to develop novel therapeutics for diseases where current treatments
are no longer as effective or do not yet exist [8]. It has two major advantages compared to de
novo drug discovery, namely reduced development time of a new chemical entity and high
probability of success as in most cases the repurposing candidate has already gone through
many stages of development for its original therapeutic use [9]. These aspects make it of inter-
est in neglected disease drug discovery where market incentives are generally low.
Several methods have been developed for repurposing drugs mostly within species but also
between species. Some of the most straightforward methods use sequences to identify gene sig-
natures, while more sophisticated methods combine sequence with protein structural informa-
tion. For example, off-target effects can be identified based on target-ligand complexes linked
by homology based on whole-sequence alignments to potential new targets [10]. Complete
protein similarity does not guarantee binding site similarity, thus new methods have been
developed that specifically investigate the proposed binding site, and can be augmented with
molecular docking and molecular dynamics simulations [11–13]. Using chemical similarities
of the ligand, rather than the target, is another widely used technique with many chemical
descriptors being developed and used in a variety of search algorithms [14, 15]. Most of these
approaches have been applied in the context of drug repurposing for human targets. In the
context of repurposing for neglected tropical disease (NTD) extra challenges are brought, as a
drug repositioned for an NTD will inevitably have to be active across different species, mean-
ing the identification of evolutionary related potential targets might be more challenging, yet
still be different enough from the host to minimise off target side effects.
Several efforts have been made in repurposing drugs for schistosomiasis. This has included
using phenotypic screens of libraries of current Food and Drug Administration (FDA)
approved drugs [16–18] as well as single target based methods [16, 19–21] and chemoge-
nomics approaches [6]. The target-based approaches tend to be formulated around a single
putative target identified from fundamental insights of helminth biology. This leads to chal-
lenges of validating the target and drug efficacy in vivo. Our own past target-based approaches
have used QSAR-based virtual screening against Schistosoma mansoni thioredoxin glutathione
reductase (SmTGR) combined with phenotypic screening [22, 23]. Phenotypic screening has
arguably been more successful in identifying drugs that work on the parasite [24], including in
vivo verification in an infectious mouse model. These studies often lack the knowledge of the
drug target, which can hinder further drug development and optimisation.
One of the dominant classes of drugs open for repurposing are kinase inhibitors due to the
huge effort to develop inhibitors targeting human kinases, successfully applied in cancer ther-
apy [25]. Kinomes of two (S. mansoni and S. hematobium) of the three major infective Schisto-
soma species of humans have been proposed [26–28]. In evolutionary terms, the distance
between Schistosoma and H. sapiens is small [29] but large enough for difference to exist, thus
similarity can be exploited from a drug discovery point of view as a human kinase inhibitor
could display activity against a helminth orthologue as well as act as a starting point to explore
new chemical series [16, 19].
Here we present a new computational approach, which combines in an innovative way
methods for remote homology detection techniques integrated with detailed knowledge of the
original drug-target interactions to identify potential new targets within a selected genome
and potential drugs to interact with those targets. These potential drugs were prioritized for
phenotypic screening to verify ex vivo activity. We have applied this methodology to schistoso-
miasis to identify potential new targets and approved drugs and verify the efficacy of these
inhibitors against all three human infective life stages of Schistosoma species. In addition, we
have elucidated the S. japonicum kinome completing the kinomes of all three major infective
Schistosoma species of humans. This, in combination with our repurposing pipeline, has
Drug repurposing and discovery for treating schistosomiasis
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allowed the identification of 22 novel schistosome potential targets, such as CHK1, CDC2,
WEE, PAKA, MEK1, ABL and suggest approved drugs that could inhibit them. These include
previously suggested schistosomicidal agents such as bosutinib, dasatinib, and imatinib as
well as newly identified drugs such as vandetanib, saracatinib, tideglusib, alvocidib, dinaciclib.
Additionally, their primary and secondary targets are also suggested and are important for
maintaining the parasite’s lifecycle.
Results
Repurposing approved drugs as novel schistosomicidal agents
The repurposing pipeline is summarised in Fig 1. Using the ChEMBL database, 1,077 drugs
were retrieved that were identified as a ‘marketed drug’ and of the drug type ‘synthetic small
molecule’. Of these, 813 drugs could be associated with a known target. The 266 unique Uni-
protKB identifiers of these targets were then collected. The difference between the number of
associated targets and the unique identifiers is due to the sets of drugs acting on the same tar-
get. The great majority of these targets were human proteins (80%), with most of the remain-
ing compounds targeting proteins in a variety of bacteria, viruses and other pathogens e.g.
Mycobacterium tuberculosis, the causative agent of tuberculosis. There were two identified tar-
gets that belong to S. mansoni: a high-voltage activated calcium channel Cav B1 subunit (Uni-
protKB ID: Q95US7) and Cav B2 subunit (UniprotKB ID: Q962H3), both of which are listed
as targets for praziquantel. No targets from S. haematobium or S. japonicum were found.
Multi-domain architectures were assigned to each of the target proteins with 194 CATH
domain superfamily assigned to 251 targets and 376 Pfam domains assigned to the entire 266
targets. Focusing on S. mansoni as the major species responsible for the disease, a similar pro-
cess of multi-domain architecture assignment was made, with 160 CATH domain superfami-
lies assigned to 1,561 proteins and 194 PFam domains assigned to 1,010 proteins. Using these
domain assignments, a total of 1,968 S. mansoni proteins were identified as potential drug
repurposing targets based on the occurrence of either a CATH or PFam domain found in the
original drug target. As the drug targets often contain domains other than those involved in
the drug interaction the number of potential repurposing targets is significantly inflated, thus
further filtering is required to identify only those potential targets that contain the correct
domain combinations involved in drug interactions.
The annotations and nomenclature found in the published structures in the PDB do not
make it easy to distinguish drug or drug-like molecules from solvent or other crystallographic
crystallization aid. We therefore manually curated a list of 326 heterogeneous atom record
identifiers including all metals, ions, peptides, nucleotides and the most common crystalliza-
tion agents and solvents. We used this list to filter the 77,230 protein structures retrieved from
the PDB that contained a ligand to obtain 39,249 structures with 15,383 unique ligands.
Of the 252 drug-targets obtained above, 143 had at least one known crystal structure and
the 39,249 structures from the PDB were filtered to find all target structures which had a drug
like ligand co-crystallized. For each structure associated with a target, the SMILES notations
for all ligands were obtained. They were then clustered against the known drug using Small
Molecular Sub-graph Detection (SMSD) with a Tanimoto coefficient of above 0.9. This
allowed for identifying structures not only that had been co-crystallized with the drug under
investigation but also very similar drug analogues. Using the filtered list of structures with
drug and drug-like compounds co-crystallised we could identify 97 FDA approved drugs
which shared a protein domain (defined from their association with a known structure) with a
domain found in a S. mansoni protein. In total 964 homologous proteins were identified in S.
mansoni that could be potential targets. All these potential targets share a domain with the
Drug repurposing and discovery for treating schistosomiasis
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original drug target, however for some of them the common domain is not involved in the
drug interaction. To overcome this, we used the original drug interactions obtained from
PDBSum and the conservation of the interacting residues to further filter the S. mansoni
potential target list to those that contained domains that could be directly involved in a drug
interaction. The resulting list contained 528 S. mansoni potential targets. The ratio of approxi-
mately one drug to six targets is broadly in line with expectations based on the number of off-
Fig 1. Overview of the drug repurposing pipeline. (A) New targets were identified in Schistosoma spp. based on domain
homology from targets of approved drugs in humans. (B) Experimental structural information of co-crystallized drugs and drug
analogues used to identify key residues involved in drug-target interactions. (C) This latter information was used to filter the results
of workflow (A). (D) Drugs whose targets were selected were screened using a phenotypic screening against all three human
infective life stages of Schistosoma. (E) As many of the filtered targets were protein kinases, we decided to the elucidate and classify
the S. japonicum kinome.
https://doi.org/10.1371/journal.pcbi.1006515.g001
Drug repurposing and discovery for treating schistosomiasis
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target interactions of compounds in humans [30]. The drug molecules identified have a broad
range of indications, dominated by kinase inhibitors, but also including but not limited to
antithrombotics, antihypertensives and antibacterials. A full list is provided in S1 Table. The
potential targets are identified without consideration for their essentialness to the survival of
the parasite to provide a list of potential targets as wide as possible. To overcome this limita-
tion, we combined target predictions with phenotypic screening to assess the drug’s potential.
Experimental validation
The 97 FDA approved drugs that could be considered for repurposing were used in a range of
phenotypic screens against different stages of the parasites left cycle. Of the drugs that could be
commercially sourced an image-based high content screen [31] was performed against the lar-
val schistosomula using a single dose of 10μM. The drug was considered a hit if the phenotype
and motility score fell below the define threshold of<-0.15 phenotype and<-0.35 motility.
The compounds that produced a larval hit were subjected to a second phenotypic screen on
juvenile worms, again at a single dose of 10 μM. Hits were considered as drugs that killed 70%
or above of the worms by day 5. These hits were used in a final single dose screen on the adult
worms, again with a hit considered as one that caused 70% mortality or above of the worms
by day 5. For these hits, IC50 were calculated for larval, juvenile and adult worms. Larval IC50
were generated from average inhibition of the HCS phenotype/motility scores while the juve-
nile and adult IC50 values were replicated by visual assessment across the dose range. Adult
IC50 values were also calculated against S. japonicum. A summary of the screen results and
IC50 values can be found in Table 1.
Extending identification of novel kinase targets
One of the main classes of compounds that emerged from our drug repurposing approach
were kinase inhibitors. This is not surprising given that they represent a significant proportion
of approved drugs and the importance of kinases in regulating cell processes. Currently, the
kinomes have been defined for two of the three main Schistosoma species that infect humans.
To provide a complete analysis of kinases across all three species and to use this to identify
novel kinase targets we built the kinome of S. japonicum as well as updated and compared the
kinomes of S. mansoni and S. haematobium with the human kinome.
The predicted proteome of S. japonicum contains 12,743 sequences, out of which we could
identify and classify 165 protein kinases using Kinannote, representing 1.3% of this organism’s
proteome. After thorough manual annotation and data integration using different strategies,
we could increase this number to 222 identified kinases or 1.7% of the proteome. The prote-
omes of S. mansoni and S. haematobium contain respectively 1.9% [26] and 2% [28] kinase
proteins. Further updates in S. mansoni [27] guided to the identification of about 2.3% kinase
proteins encoded by its proteome. Our results show that the kinome of S. japonicum is com-
posed of proteins belonging to the nine major eukaryotic protein kinase (ePK) groups. Table 2
shows an overview of the draft and final S. japonicum kinome classification, including the
number of proteins added by the described pipeline.
Our pipeline (see Fig 2A) allowed the classification of 222 protein kinases into eight major
ePKs groups and, among them, seven proteins were assigned only at “group” level, 103 at
“family” level, and 111 at subfamily level (see S2 Table for the annotation details of the S. japo-
nicum kinome). Phylogenetic trees for the major eight kinase families were constructed, and
the positioning of the proteins within each group also reflects their further sub-classification
into families and sub-families, and their complex interrelatedness (Fig 2B). Regarding the role
of the identified kinases, functional annotation gathered from KEGG database revealed that
Drug repurposing and discovery for treating schistosomiasis
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most of them are involved in cellular processes such as cell communication, cell growth and
death, and cell motility and development (Fig 2C).
The elucidated, classified and annotated S. japonicum kinome can be summarized as fol-
lows and visualised in S1 Fig. The CMGC group, which includes mitogen-activated protein
Table 1. Summary of phenotypic screening results. A summary of the top hits from the phenotypic screening of larval, juvenile and adult S. mansoni worms as well as
adult S. japonicum worms for those hits that were successful in S. mansoni. Screen hits are shown, along with motility (as a percentage) and IC50 values (uM). The High
Content Screening (HCS) larval assays were parametrised with positive controls with Oltipraz to define phenotype and mobility values with average scores of -0.66 for phe-
notype and -0.92 for mobility. The juvenile and adult assays followed a previously reported method which included appropriate positive controls (see Methods). To mini-
mise animal usage, only where a ‘hit’ was obtained further screening was performed, starting with larval progressing to juvenile and then adult for S. mansoni then
following up for adult S. japonicum.
Compound
name
Larva HCS
Hit 10uM
Juvenile
Hit Day 5
10uM
Juvenile
Motility
Adult
Hit Day
5 10uM
Adult
Motility
Larva
IC50
(HCS)
(uM)
Larva
IC50
(Visual)
(uM)
Juvenile
IC50
Juvenile IC50
(Reproduced)
Mean
Juvenile
IC50 (uM)
Adult
IC50
(uM)
Adult S.
Japonicum
IC50 (uM)
Bosutinib HIT HIT 95.8 HIT 87.5 10.49 10.39 0.7977 0.9552 0.88 1.84 7.092
Crizotinib HIT HIT 78.6 HIT 70.8 6.45 6.49 3.268 1.347 2.31 3.336 N/A
Sunitinib Malate HIT HIT 83.3 N 62.5 4.95 6.37 4.595 2.01 3.30 3.703 N/A
Nilotinib HIT HIT 75 HIT 91.7 6.57 10.09 6.455� 4.648 4.65 3.924 N/A
Dasatinib HIT HIT 90 HIT 70.8 4.66 4.94 1.542 1.303 1.42 4.594 5.266
Imatinib
mesylate
NON_HIT HIT 92.9 HIT 75.0 15.21 15.63 5.713 4.436 5.07 8.124 19.03
Alendronate
Sodium
NON_HIT HIT 79.2 N 62.5 >25 >25 1.388� 7.201 7.20 >20 N/A
Tamoxifen
Citrate
HIT HIT 95.8 N 29.2 3.73 4.07
Ibandronate
Sodium Salt
NON_HIT HIT 89.3 N 16.7 >25 13.01
Triclosan HIT HIT 85.7 N 45.8 3.75 4.46
Toremifene
Citrate Salt
HIT HIT 75 N 0.0 3.40 3.36
Lapatinib HIT N 37.5
Diethylstilbestrol HIT N 25
Risedronate
Sodium
NON_HIT N 58.3
Atorvastatin
Calcium
NON_HIT N 41.7
https://doi.org/10.1371/journal.pcbi.1006515.t001
Table 2. Summary of S. japonicum kinome, from its initial classification to the final classification of protein
kinases.
Kinase groups Draft Final Manually added
AGC 22 27 5
CAMK 26 33 7
CK1 7 8 1
CMGC 35 41 6
Other 23 35 12
RGC 1 4 3
STE 17 23 6
TK 19 31 12
TKL 8 13 5
PKL/aPKs 7 8 1
Total 165 222 58
https://doi.org/10.1371/journal.pcbi.1006515.t002
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kinases (MAPK), cyclin dependent kinases (CDKs) and kinases involved in splicing and
metabolic control, was the largest group represented, with 34 protein kinases. From these, 13
kinases belong to the CDKs family, 10 to MAPKs, six dual-specificity tyrosine-regulated
kinases (DYRKs), four CDC-like kinase (CLKs), two glycogen synthase kinases (GSKs), CDK-
like (CDKLs) and SRPK, and one member belonging to CK2 family. The CAMK (Calcium
and Calmodulin-regulated kinases) group was represented by CAMKs, CAMK-related
kinases, MAPKAPK (MAP kinase activated protein kinase), and DAPKs (death-associated
protein kinases). Among tyrosine kinase (TK) group, 15 proteins were represented by RTKs
(receptor tyrosine kinases) and 13 by CTKs (cytoplasmic tyrosine kinases) and three members
were not classified at family level. The AGC group comprised 27 proteins, including PKAs,
PKCs, PKGs, DMPKs and RSKs. The STE group had 23 members, comprising 14 members
of STE20 (MAP4Ks), 5 members of STE11 (MAP3Ks) family, and 4 members of STE7
(MAP2Ks) family. There were 13 proteins assigned to tyrosine kinase-like (TKL) group and
belonging to families such as LISK (n = 2), RAF (n = 3), LRRK (n = 2), MLK (n = 2), and
STKR (n = 5). Eight proteins were assigned to CK1 group, including VRK (vaccinia-related
kinase) and TTBK (Tau tubulin kinase) families. Furthermore, our annotation also assigned 7
Fig 2. (A) General pipeline for the S. japonicum kinome construction. (B) Venn diagram displaying the overlap of proteins
clusters between the three most clinically important species of Schistosoma. (C) Final analysis of functional annotation step:
cellular processes in which S. japonicum kinases are enrolled.
https://doi.org/10.1371/journal.pcbi.1006515.g002
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proteins to PKL group (ABC1 and RIO families). Four proteins classified into receptor guany-
late cyclases (RGC) group, the smallest kinase group in S. japonicum kinome. Thirty-five pro-
teins that did not belong to any of the major kinase groups were placed into “Other” including
AUR (aurora kinase) and PLK (Polo-like kinase). A single protein was classified as an atypical
kinase, assigned to PIKK family. This protein (sequence accession Sjp_0039160) has no ortho-
logs in neither S. haematobium nor in S. mansoni [28] and in a BLAST search against Worm-
Base (https://parasite.wormbase.org/index.html) one can find it classified as a PIKK protein in
Echinococcus multilocularis, a cestoda worm responsible for echinococcosis.
Subsequently, we developed a target prioritization workflow using a topological network
analysis. A protein-protein interaction network was constructed based on evidence gathered
from S. mansoni orthologs deposited in STRING database [32]. Proteins were organized into
modules according to indices of topological centrality, allowing the characterization of their
biological importance.
The combination of at least two centrality measures has been proposed as a suitable strategy
in defining essential genes in biological networks [33]. In biological terms, a betweenness cen-
trality metric can indicate the relevance of a protein considering its capability of connecting
different parts (processes) of the network. Considering that kinases are especially involved in
signalling processes, this metric is relevant to our work. In the same way, the closeness metric,
applied in a biological context, can be used as a measure of how fast the information from one
node can spread to other nodes in the network, which is also of interest in the signalization
context. Subgraph centrality analysed “closed walks” in the network, i.e., the importance of the
protein in subnetworks, allowing better ranking in comparison to the whole network and bet-
ter discrimination among the proteins [34] S2 Fig. Using this approach, we identified a list of
26 protein kinases highly relevant for the interaction network generated from STRING data-
base [32], that could be prioritized as new potential drug targets.
Discussion
The identification of novel indications for existing licenced therapeutics offers an attractive
route for neglected topical diseases drug discovery, with the potential to reduce development
time and costs and decrease the likelihood of failure in clinical testing. Thus, we developed a
novel computational repurposing pipeline (summarised in Fig 1) exploiting conserved drug-
target interaction properties in distantly evolutionary related potential targets. Predictions
were supported by phenotypic screening on different infective life stages and species of
Schistosoma.
The top hits from the phenotypic screening are from a series of tyrosine kinase inhibitors
developed as first line (imatinib) and second line (bosutinib, crizotinib, nilotinib, dasatinib)
anti-cancer treatments for chronic myelogenous leukemia (CML). Imatinib has already been
identified as a possible drug-repurposing candidate based on the homology between the
human gene target and a gene in the Schistosoma genome during its annotation [35–37]. The
second line treatments have recently been identified from larval and follow-up adult pheno-
typic screening [38]. These independent observations validate the approach used here. Though
many of our hits agree with previous studies some, such as nilotinib, show different ex vivo
activity in contact to previous findings [39]. Differences between screens have been observed
before [17] and does not mean that either are incorrect: differences in strains used, concentra-
tions of compounds, duration of assessment, DMSO concentrations, if the adults were paired
or un-paired, and if un-paired if they were all male, all female or mixed can all have an effect.
Though the potency of these compounds is promising, they are not immediately of the
quality required of a lead compound or directly transferable to the clinical setting. However,
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they provide excellent starting point to begin to explore variations of the compound within
the same chemical series. As we have knowledge of the potential targets of these compounds,
including the ability to generate molecular models, it will be possible to explore Schistosoma
specific features of the proposed targets to design compounds with higher potency using
ligand-based and structure-based drug design. It is important to note that the top hits showed
potency against all three life-stages, including juvenile worms that is a known short coming of
PZQ activity [40, 41]. By using a combination of target-based remote homology detection and
phenotypic screening, this dual method can provide more information than either of the two
approaches separately. This includes the detection of several potential targets for these com-
pounds beyond the two genes annotated as homologs of the human target gene (see Fig 3).
This comprises several proteins that are, as yet, not annotated with any function. In addition,
by using a structure-based approach, structural models of the new potential targets can be pre-
dicted and docking can be performed with the repurposed compound (see Fig 4). This allows
for exploration of novel binding modes and elaboration or virtual screening of analogue
Fig 3. Alignment and conservation of key residues involved in new targets to tyrosine kinase inhibitors. The key residues involved in drug/
target interactions (shown bottom) are highlighted by arrows in structurally informed multiple sequence alignment (using Taylor conservation
colouring) for the potential repurposing targets identified in Schistosoma mansoni. Three tyrosine kinase inhibitors are shown: Imatinib (blue),
Dastinib (red) and Bosutnib (black).
https://doi.org/10.1371/journal.pcbi.1006515.g003
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compounds to exploit features that are pathogen-specific. Though phenotypic screening
remains a gold standard for assessing if the potential re-purposed drugs are effective against
the worm, it would be possible to integrate other sources of data that hold information relating
to how essential the potential target might be to the parasite. This could be introduced as a fur-
ther triage step in the computational pipeline.
Only a relatively small fraction of the suggested repurposed compounds lead to success
with all three infective life stages in phenotypic screening. For example, sodium alendronate,
Fig 4. Modelling targets of imatinib. Structural models of the targets (ABL1, ABL2, TK3_SM, TK5_SM, Smp_006920, Smp_128550, Smp_125360)
identified in Schistosoma mansoni (shown as cartoon in blue) of imatinib, which is docked to the targets (shown as sticks in red).
https://doi.org/10.1371/journal.pcbi.1006515.g004
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an osteoporosis treatment that targets farnesyl diphosphate synthase, has many of the residues
involved in drug interaction conserved in three homologues identified by the pipeline (see Fig
5). Also, the drug has proved success in assays against farnesyl diphosphate synthase in Leish-
mania donovani. However, in phenotypic screening it did not produce a hit. This could be due
to low bioavailability of the drug in the worm or the lack of expression of the target. This dem-
onstrates the necessity of using a combination of target-based approaches with phenotypic
screening.
As many of the predictions were kinase inhibitors, we also undertook an extensive and
though investigation of the kinomes of all three infective Schistosoma species, including the yet
unexplored kinome of S. japonicum, to suggest new targets and novel schistosomicidal agents.
Among the obtained list of prioritized 26 protein kinases, the CAMK group was the most rep-
resented, with four CAMKL family members and one PIM family member, followed by the
AGC group, with one member in each family RSK, PDK1, SGK, PKA, and PKG. The group
“Other” was also represented by five members of families AUR, PLK, TTK, WEE, and NAK,
while CMGC and STE groups were represented by four proteins, belonging respectively to
families CDK, MAPK, and GSK; and STE7, STE11, and STE20, respectively. The smallest
group was TKL with two members of families LRRK and RAF.
Fig 5. Alignment and conservation of key residues involved in new targets to alendronate sodium. The key residues involved in drug/target interactions (shown
bottom) are highlighted by arrows in structurally informed multiple sequence alignment (using Taylor conservation colouring) for the potential repurposing targets
identified in Schistosoma mansoni. The residues involved in drug interactions are spaced across the alignment, therefore only the relevant sections of the alignment are
shown for clarity.
https://doi.org/10.1371/journal.pcbi.1006515.g005
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After predicting these kinases as potential drug targets, we interrogated drug databases to
search for drugs that could interact with one or more of these potential targets. Table 3 shows
the sample information about five of these kinases; additional information, including approved
drugs for identified essential kinases and prioritized potential targets list is available in S3
Table.
Of those 26 kinases prioritized after the centrality analysis step, 15 proteins had orthologs
in the list of 528 potential targets gathered from our protein domain based approach for drug
repurposing. Of those 15 S. japonicum kinases, 5 kinases were assigned only to lithium citrate,
an approved drug for treating psychotic disorders; 10 kinases were assigned to 16 approved
drugs, including bosutinib, dasatinib, and imatinib, which were the best experimentally vali-
dated hits in our phenotypic screening assays. The protein kinases involved in interactions
with those drugs are: CMGC/CDK/CDC2; STE/STE20/PAKA; CAMK/PIM; CMGC/MAPK/
ERK; CMGC/MAPK/p38; CMGC/GSK; AGC/PKA; CAMK/CAMKL/NIM1; Other/AUR;
Other/TTK. Some representing kinases of those prioritized groups, were identified as possible
targets of bosutinib, dasatinib, and imatinib, are well as some kinases well characterized in the
literature, such as PKA, PLK, p38, and ERK. The Other/AUR kinase is more related to trypa-
nosomatid protozoan parasites [42, 43]. Therefore, this kinase is suggested as one of the novel
biological targets for killing Schistosoma genus parasites.
Cyclic AMP (cAMP)-dependent protein kinase/protein kinase A (PKA) have been mapped
in both male and female worms and localized in its activated state. A consistent correlation
has been established between PKA and tegument, somatic musculature, seminal vesicle and
gynaecophoric muscles [44]. Polo-like kinases (PLK) represent a conserved group of cell-cycle
regulators and, in S. mansoni, PLK1 and Sak kinases have been described as a confirmed game-
togenesis regulator [45–47] and an important protein in gonad maturation [47] respectively.
ERK kinase is a validated target in S. mansoni [48]. The effects on worm coupling, reduc-
tion of egg release, and worm homeostasis were pronounced [45, 46, 49]. A connection
between PKC and ERK signalling has been observed [49], turning these proteins into inter-
esting points of intervention in the context of schistosomiasis treatment. Mitogen-activated
p38 kinase is a highly conserved protein kinase in different species, described in S. mansoni
with a key role in transition between two life stages of this trematode [50]. This highlights
the enormous importance of kinase proteins as biological targets in the search of new treat-
ments for schistosomiasis.
A limitation of our S. japonicum kinome elucidation approach include the use of a reference
S. japonicum genome (and, consequently, proteome) that cannot be considered a definitive
picture of all genes and proteins coded by S. japonicum. The S. japonicum genome described
by Zhou et al. [51] that we used during the determination of the kinome repertoire was
sequenced using a traditional Sanger instrument in 2009 and, while that usually associates to
Table 3. Top 5 prioritized kinases as potential schistosomicidal targets and its human identity (%).
ID Classification Functional annotation Human identity (%) Kinase SARfari
Bioactivitesa Number of compounds
Sjp_0031130 CMGC/CDK/CDC2 Cell growth and death 66 2971 2531
Sjp_0035520 CMGC/MAPK/ERK1 Cell growth and death 57 1068 1417
Sjp_0046880 Other/AUR Cell growth and death, oocyte meiosis 45 1913 1613
Sjp_0054140 Other/PLK/SAK Signal transduction 36 196 167
Sjp_0026020 CMGC/GSK Signal transduction 73 3449 2744
a: available screening data related to each protein kinase that was found at Kinase SARfari online platform (https://www.ebi.ac.uk/chembl/sarfari/kinasesarfari)
https://doi.org/10.1371/journal.pcbi.1006515.t003
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good base qualities, the throughput obtained is much lower than current NGS instruments.
Using evidence from full length cDNAs (flcDNAs) and expressed sequence tags (ESTs) avail-
able then, the authors reported a coverage >90% of their published S. japonicum genome. As
such, it is possible that we may have missed some kinases that could not be predicted using our
approach because the underlying sequences were not present in the proteome reference used.
Through the development of a new computational pipeline to suggest novel indications for
currently approved drugs and supported by phenotypic screening, several new targets and
drugs have been suggested as starting points in the development of new schistosomicidal
agents. As many of these new targets and drugs are kinases and kinase inhibitors, we under-
took a detailed and extensive comparative analysis of the kinomes of all three human infective
Schistosoma species and the human host. This allowed the identification of kinase targets and
existing and novel inhibitors that could be effective across all three Schistosoma species. The
computational drug repurposing pipeline is generalizable, as it only requires a change in the
target genome identifier for it to be applied to other infectious disease agents.
Materials and methods
Ethics statement
Experimentation was carried out using the NC3Rs and ARRIVE guidelines under the United
Kingdom Animal’s Scientific Procedures Act 1986 with approval from the London School of
Hygiene and Tropical Medicine Ethics committee. Male CD1 mice (aged 5–6 weeks) were
bred on site using SPF conditions with access of food and water ad libitum.
Drug repurposing pipeline
A computational drug repurposing pipeline was developed to predict potential drugs that
could be repurposed as antischistosomal compounds. An overview of the pipeline is shown in
Fig 1. Data for all currently FDA approved drugs and their known molecular targets was col-
lected from ChEMBL database v. 18 [52]. The multi-domain architecture for these drug-targets
was defined using a combination of CATH-Gene3D [53] and Pfam [54], via ArchSchema [55].
The same process of multi-domain architecture definition was conducted on the non-redun-
dant set of Schistosoma mansoni proteins in UniprotKB [56]. CATH structure based domains
were clustered using the agglomerative clustering tools associated in the alignment generation
steps used in FunTree [57] (Fig 1A). This generates an association by individual protein
domain between current drug targets and equivalent domains in protein from S. mansoni.
Concurrently, using the target associations obtained from ChEMBL, any known crystal
structures were collected from the Protein Data Bank (PDB) [58], removing structures that
only contain ions, metals, crystallographic solvents or aids as ligands (Fig 1B). A list of the het-
erogeneous atom records used in this exclusion can be found in S4 Table. For each target, the
remaining structures were clustered with the FDA-approved drugs based on the similarity to
the co-crystalized ligands using Small Molecular Sub-graph Detection (SMSD) [59] with a sim-
ilarity threshold of 0.9 computed using the Tanimoto coefficient (Fig 1B). This allowed for
similar drug analogues to be picked up where the actual drug had not been co-crystallized.
Automatic structural analysis to identify the residues within the structure responsible for the
interaction between the ligand and its target was identified using PDBSum [60].
The ligand-target interaction information was combined with the domain similarity clus-
tering (Fig 1A and 1B) to remove domains that were not involved with the interaction and to
filter for those domains where these specific residues were conserved. For each target, a list of
proteins in S. mansoni that contained a homologous domain where there is conservation of
ligand binding residues could be retrieved. These represent the potential repurposed drug
Drug repurposing and discovery for treating schistosomiasis
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targets (Fig 1C). Based on this association, molecular structural models of the domains could
be automatically generated using MODELLER [61]. The drugs whose targets were selected by
this pipeline were screened using a phenotypic screening strategy against all three human
infective life stages (Fig 1D).
Construction of the S. japonicum kinome
As a first step towards defining the S. japonicum kinome, we downloaded its proteome from
the GeneDB database (http://www.genedb.org/Homepage/Sjaponicum). The kinomes of S.
mansoni [26] and S. haematobium [28] were used as sources of orthologs to compare the pro-
tein kinases of S. japonicum. Weight was placed on orthologs from S. mansoni that is phyloge-
netically closer to S. japonicum than S. haematobium. This approach was complemented by
using the Kinannote software [62] using the -m option for metazoan organisms, allowing the
generation of a draft S. japonicum kinome. After this initial prediction, sequences that were
not classified were manually curated and re-classified as far as possible. The work flow is sum-
marised in Fig 2A.
Orthologous sequences were predicted through OrthoMCL [63] by pairwise sequence com-
parison between kinases of S. mansoni and S. haematobium, grouping S. japonicum proteins to
kinases and were not classified previously by Kinannote. Using UniProt database [56] and the
InterProScan webserver [64] to identify the kinase domains of each protein previously pre-
dicted and classified, and to determine a consensus localization of the catalytic domain.
Kinome tree generation
For construction of phylogenetic trees per individual kinase family, multiple sequence align-
ments of the amino acid sequence spanning the consensus catalytic domains of each protein
were made using MAFFT v. 7.215 in most accurate mode (L-INS-i) [65], followed by refine-
ment using MUSCLE v. 3.8.31 (—refine parameter) [66]. The selection of an evolutionary
model for maximum likelihood (ML) tree reconstruction was performed using ProtTest3 [67].
ML trees were generated using PhyML 3.0 [68] with 1,000 bootstrap replicates. FigTree (avail-
able at http://tree.bio.ed.ac.uk/software/figtree/) was used to edit and export the trees.
Prioritising kinase targets
For the kinase prioritisation as biological targets, we performed an integrative analysis, using,
the Kyoto Encyclopaedia of Genes and Genomes (KEGG) database [69] as a resource for func-
tional annotation and pathway contextualization of the classified kinases with the BlastKOALA
analysis tool (http://www.kegg.jp/blastkoala/). In parallel, the kinomes of S. mansoni, S. hae-
matobium, and S. japonicum were compared using the OrthoVenn webserver [70] to group
kinases into clusters and to identify the number of common clusters among these three species
(see Fig 2B). Data from the STRING database [71] was used to construct a protein-protein
interaction network. For this purpose, the predicted, curated, and annotated kinome of S. japo-
nicum was used as input and the webserver automatically recovered the best hits from S. man-
soni proteins deposited in the database. Then, a network of 214 orthologous kinase proteins
was generated and allowed the identification of relationships among those proteins. Other rel-
evant information about these proteins, e.g., co-expression profiles, existence of three-dimen-
sional crystal structure, etc. were gathered to enrich the annotation. The interaction network
was exported from STRING and analysed within the Cytoscape platform (v. 3.4.0, http://www.
cytoscape.org/), which allows for data integration, topological analysis, and visualization [72].
Local and global centrality metrics were calculated using cytoNCA plugin [73] for each protein
in the network and, after manual curation, only a subnetwork containing the most important
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proteins for the entire network was kept. In addition, we conducted searches in the DrugEBI-
lity portal (https://www.ebi.ac.uk/chembl/drugebility/) to gather further information about the
prioritized targets, including their identity with human orthologous proteins, related bioactiv-
ity data, and drugs potentially targeting those kinases (see S2 Fig).
Parasite maintenance and preparation
All experiments performed using S. mansoni utilized the Puerto Rican strain and was main-
tained through Biomphalaria glabrata and CD1 mice. Schistosoma japonicum, Philippine
Strain, was maintained through Oncomelania hupensis subsp. quadrasi and CD1 mice (BEI
resources, MD, USA). Schistosomula were prepared and isolated using a percoll gradient as
previously described [24].
S. mansoni juvenile or adult worms were recovered by perfusion 3 or 6 weeks later respec-
tively from mice infected subcutaneously as previously described [24]. For S. japonicum
worms were generated using the same technique but with a 6 or 12-week incubation period
for juvenile or adults respectively. Recovered S. mansoni and japonicum worms were then
washed free of blood and placed into culture.
The schistosomula generated were incubated over- night in M169 supplemented with
100U/ml Penicillin, 300μg/ml Streptomycin, 0.25μg/ml Fungizone (Amphotericin B) (Gibco,
UK) and 5% Foetal Calf serum. For production of S. mansoni juvenile or adult worms, mice
were infected subcutaneously under mild isoflurane (Merial Animal Health Ltd (UK)) anaes-
thesia with, respectively 1400 (for juveniles) or 450 cercariae (for adults). Worms were recov-
ered from infected mice using sterile techniques by portal perfusion 3 weeks (for juveniles) or
6 weeks (for adults) post-infection using warm perfusion medium (Dulbecco’s Modified
Eagle’s Medium [DMEM], 2mM L- glutamine, 100 Units/ml penicillin, 100μg/ml streptomy-
cin, 20mM Hepes, 10 Units/ml heparin [Sigma, UK]. Adult worms were washed free of red
blood cells using the perfusion medium, and finally placed in culture in complete medium
(cDMEM: DMEM, 2mM L-glutamine, 100 Units/ml penicillin, 100μg/ml streptomycin, 10%
foetal calf serum (FCS) at 37˚C, in an atmosphere of 5% CO2. Juvenile worms were sedi-
mented successively following washing with cold perfusion medium and then suspended in
cold cDMEM until dispensed to avoid attachment to the plastic tubes.
High-content schistosomula screening assays
The larval High-Content Screening (HCS) was run as described previously [31]. Briefly cul-
tured schistosomula were cultured for 72 hours in absence or presence of compound. After a
gentle re-suspension using a Biomek FxP to generated an even distribution of parasites across
the well, images were collected at 10x for phenotype analysis and at 4x over a time-series for
motility analysis using an Image Xpress micro (Molecular devices, USA). Image analysis was
then conducted using Pipeline Pilot 9.0 (Biovia, USA). Phenotype analysis was conducted
using a previously validated two class Laplacian-modified Bayesian categorization model built
using standard schistosomacides and motility analysis by individual parasite area displacement
over the time series [31]. To generate larval IC50s the percent inhibition at specific compound
concentrations were calculated by comparison to the mean DMSO scores (32 wells) on each
plate. These were then imported into Prism 6 (Graphpad) to generate IC50 values.
Juvenile and adult worm screening assays
For the juvenile assay 5–8 individual worms and the 3 adult worm pairs were cultured in the
absence or presence of compound for 5 days [24]. Drug effects were then determined by
assessing the viability of individual worms as described by Ramirez et al [74] and calculating
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the mean percentage inhibition, a hit being defined as�70% reduction in viability. To calcu-
late IC50 against juvenile or adult worms the percent inhibition were plotted against drug
concentration in Prism 6 (Graphpad). To minimise the number of animals used, only those
compounds that were considered a hit were tested further to obtain IC50 values.
Supporting information
S1 Table. Summary of potential schistosomicidal repurposed drugs.
(XLS)
S2 Table. Draft kinome of S. japonicum and some relevant information, including ortholog
proteins in S. mansoni.
(XLSX)
S3 Table. Prioritized kinases as potential schistosomicidal targets.
(XLSX)
S4 Table. A curated list of heterogeneous atom records used as part of the filter of non-
drug like co-crystallised compounds from the PDB.
(CSV)
S1 Fig. Kinome tree of S. japonicum. All major kinase groups are represented above, except
the atypical kinase group. Individual trees were constructed for each group and a human rep-
resentative kinase in each group was used for rooting the tree. Black circles indicate bootstraps
higher than 60%.
(PNG)
S2 Fig. Potential biological targets for new schistosomicidal agents identified through the
described bioinformatic pipeline. Size of each node in the left network is displayed accord-
ingly to its Degree metric: the bigger the size, more connected the node. Blue protein-protein
interaction network was gathered from STRING webserver and analyzed in Cytoscape v.3.4.0,
where centrality metrics was calculated through cytoNCA plugin and a subnetwork was gener-
ated from highlighted nodes. In concordance to calculated metrics, highlighted nodes are
essential for the protein-protein interaction network and, in a biological context, they were
prioritized as potential biological targets for new schistosomicidal agents.
(PNG)
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